Kyverna Therapeutics, Inc. (KYTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kyverna Therapeutics, Inc., a Delaware corporation and emerging growth company, on December 17, 2025. The report details the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 13,333,333 shares of Common Stock.
- Public Offering Price: $7.50 per share.
- Underwriting Price: $7.05 per share.
- Gross Proceeds: Approximately $100 million (before deducting underwriting discounts, commissions, and offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 1,999,999 shares.
- Use of Proceeds: General corporate purposes, including funding research and development, capital expenditures, working capital, and general and administrative expenses.
- Expected Closing: On or about December 18, 2025.
Note: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with J.P. Morgan Securities LLC, Leerink Partners LLC, and Morgan Stanley & Co. LLC as representatives. The offering is being made pursuant to a previously effective Form S-3 registration statement (File No. 333-286180).
Additionally, directors, executive officers, and certain affiliated stockholders have entered into "lock-up" agreements prohibiting the sale or transfer of securities until January 31, 2026, subject to exceptions.
Outlook, Risks, and Contingencies
The closing of the offering is subject to the satisfaction of customary closing conditions. The filing includes forward-looking statements regarding the anticipated closing and use of proceeds, which are subject to risks and uncertainties, including market conditions and the Company's ability to satisfy closing conditions on a timely basis.
Key Facts for Investor Verification
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and offering expenses.
- Confirm whether the underwriters exercise the over-allotment option to purchase the additional 1,999,999 shares.
- Review the Company's most recent periodic reports (10-K or 10-Q) for current cash balances and burn rate to assess the impact of the new capital.
- Monitor the lock-up expiration date of January 31, 2026, for potential selling pressure from insiders.